Aliskiren (fumarate)

Aliskiren fumarate is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren fumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia[1][2][3].

Product Specifications

CAS Number

[1196835-68-3]

Product Name Alternative

CGP 60536 (fumarate) ; CGP60536B (fumarate) ; SPP 100 (fumarate)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Autophagy; Renin

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/aliskiren-fumarate.html

Solubility

10 mM in DMSO

Smiles

O=C(O)/C=C/C(O)=O.COCCCOC1=CC(C[C@@H](C[C@@H]([C@H](C[C@H](C(NCC(C)(C(N)=O)C)=O)C(C)C)O)N)C(C)C)=CC=C1OC

Molecular Formula

C34H57N3O10

Molecular Weight

667.83

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501

References & Citations

[1]Yuji Nakamura, et al. Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ACS Med. Chem. Lett., 2012, 3 (9), pp 754–758|[2]Wood JM, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 Sep 5;308 (4) :698-705.|[3]Wang C, et al. Aliskiren targets multiple systems to alleviate cancer cachexia. Oncol Rep. 2016 Nov;36 (5) :3014-3022.